INDOCOBSEIndoco Remedies LtdHighPositive
Announced Thu, 28 May · 16:23 IST

Indoco''s formulation plant at Baddi (Plant III) receives EU GMP Certification

Regulatory Product ApprovalBusiness Updates View source PDF

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.9%1-day move
₹203.00
prior close
₹214.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+0.1-0.1-1.8+3.9+2.0+1.9+4.7+2.5+2.0+14.9+14.6
Up moveDown movePending
AI summary

German Health Authority (Berlin) inspected Indoco Remedies' Oral Solid Dosage (OSD) manufacturing facility at Baddi (Plant III) from April 22-27, 2026, and the facility has received EU GMP certification confirming compliance with EC Directive Good Manufacturing Practice requirements. This certification validates the quality standards of the facility and enables the company to supply pharmaceutical products to European Union markets. Indoco is a fully integrated pharmaceutical company with US$ 175 million turnover, operating 10 manufacturing facilities with approvals from major regulatory bodies including USFDA and UK-MHRA.

Likely market impact

This EU GMP certification enhances Indoco's ability to export formulations to European markets, potentially leading to new business opportunities and hard currency revenues. It validates the company's manufacturing quality standards to global regulatory benchmarks.